Related Experiment Video
Updated: Jan 16, 2026
08:55
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
12.8K
Cure of Recurrent Ovarian Cancer: A Multicenter Retrospective Study
Masahiro Sumitomo1,2, Yasushi Kotani1, Kosuke Murakami1
1Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osakasayama 589-8511, Japan.
Cancers
|September 27, 2025
Summary
Approximately 10% of recurrent ovarian cancer patients achieve a 4-year disease-free survival (DFS) and are considered cured. Characteristics of cured cases and criteria for cure were identified in this study.
Area of Science:
- Oncology
- Gynecologic Oncology
- Cancer Research
Background:
- Recurrent ovarian cancer has a poor prognosis, with limited curative potential.
- Identifying criteria for cure and characteristics of cured patients is crucial.
Purpose of the Study:
- To define criteria for cure in recurrent ovarian cancer.
- To identify patient and tumor characteristics associated with cure.
Main Methods:
- Analysis of recurrent ovarian cancer cases from university and community hospitals.
- Assessment of complete remission (CR) and no evidence of disease (NED) status.
- Inclusion of BRCA1/2 mutation analysis in tumor samples.
Main Results:
- 13% of recurrent cases achieved no evidence of disease (NED).
- Cured cases (NED) showed lower initial ascites, longer disease-free survival (DFS), solitary lesions, and higher rates of secondary debulking surgery.
- A 4-year DFS was established as a criterion for cure in complete remission (CR) cases.
- BRCA pathogenic variants were found in 5/11 high-grade serous carcinoma (HGSC) cases achieving 4-year DFS.
Conclusions:
- Around 10% of recurrent ovarian cancer patients achieve a 4-year DFS, indicating a high likelihood of cure.
- Cure in non-HGSC cases was independent of pathogenic BRCA variants.
- This study provides insights into the curability and prognostic factors in recurrent ovarian cancer.
Related Concept Videos
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:21Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648